Ellicott City, MD – SCRS and Eli Lilly & Company today announced a Site Engagement Partnership, which allows for significant involvement and increasing direct communication with the sites. Through this partnership, Lilly brings their commitment to excellence to site development and site sustainability. “SCRS welcomes this significant partnership with Lilly, who has been a strong Global Impact Partner since 2013,” said Christine Pierre, President of SCRS. “Lilly is taking a significant leadership role in bolstering its commitment to site sustainability and continuing to connect site members with patient-centered movements in clinical research.” “Lilly greatly values our partnership with SCRS as we work together to enhance the strengths and address the challenges of conducting clinical research, particularly through the close collaborations with investigative sites. We are excited to increase our areas of SCRS global participation, further indicating our commitment to incorporating site feedback and being involved in development of solutions to achieve the mutual goal of bringing new medicines to patients,” stated Meri Kay Scott, Senior Director, Global Clinical Operations, Eli Lilly and Company. About SCRS SCRS is a global trade organization founded in 2012 which represents over 4,000 research sites in 54 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org. About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Lilly was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today the company remains true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. For more information, visit www.lilly.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.